Menu Search
Equities

Lupin Ltd

LUPIN:NSI

Lupin Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,071.35
  • Today's Change30.35 / 1.49%
  • Shares traded410.40k
  • 1 Year change+70.06%
  • Beta0.7405
Data delayed at least 15 minutes, as of Nov 22 2024 10:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Lupin Ltd grew revenues 20.25% from 166.42bn to 200.11bn while net income improved 345.15% from 4.30bn to 19.14bn.
Gross margin68.60%
Net profit margin12.37%
Operating margin15.86%
Return on assets10.84%
Return on equity18.19%
Return on investment16.64%
More ▼

Cash flow in INRView more

In 2024, cash reserves at Lupin Ltd fell by 2.48bn. However, the company earned 36.48bn from its operations for a Cash Flow Margin of 18.23%. In addition the company used 17.12bn on investing activities and also paid 21.84bn in financing cash flows.
Cash flow per share80.23
Price/Cash flow per share25.40
Book value per share342.91
Tangible book value per share249.82
More ▼

Balance sheet in INRView more

Lupin Ltd has a Debt to Total Capital ratio of 17.97%, a higher figure than the previous year's 1.16%.
Current ratio1.88
Quick ratio1.22
Total debt/total equity0.2201
Total debt/total capital0.1797
More ▼

Growth rates in INR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 100.00% and 344.87%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
Div yield(5 year avg)0.62%
Div growth rate (5 year)9.86%
Payout ratio (TTM)13.88%
EPS growth(5 years)30.00
EPS (TTM) vs
TTM 1 year ago		97.08
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.